← Back

Sangamo Therapeutics Inc

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; small fiber neuropathy for chronic neuropathic pain, and prion disease; Phase 1/2 clinical trial to evaluate the safety and tolerability of the investigational genetically modified cell therapy TX200 in patients undergoing a kidney transplant.; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; giroctocogene fitelparvovec, a Phase 3 study to evaluate the clinical efficacy and safety of giroctocogene fitelparvovec gene therapy in adult male with moderately severe or severe hemophilia A. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Genentech, Inc.; Astellas Gene Therapies, Inc.; Capsid Delivery License Agreement with Eli Lilly and Company; Alexion Pharmaceuticals, Inc. " ALS and Frontotemporal Lobar Degeneration; Takeda " Huntington's Disease; and other areas, such as plant agriculture and research reagents, including the production of transgenic animals and cell-line engineering with Corteva AgriScience and Open Monoclonal Technology, Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. The company was incorporated in 1995 and is headquartered in Richmond, California.

Price · split & dividend adjusted
News & notes moving SGMO
Biotech & Genomic Medicine▲

PTC Therapeutics to Acquire ST-920 Gene Therapy for Fabry Disease

PTC Therapeutics has agreed to acquire ST-920, a BLA-stage one-time AAV gene therapy for Fabry disease, from Sangamo Therapeutics in a $111 million upfront deal plus milestone payments. ST-920 is designed to deliver a functional copy of the GLA gene using an adeno-associated viral vector, and in the Phase 1/2 STAAR study patients showed sustained enzyme activity for up to 4.5 years alongside improvements in renal function, cardiac outcomes, and quality of life. The BLA submission for accelerated approval is based on the intermediate clinical endpoint of annualized eGFR at Week 52, with nonclinical and clinical modules already submitted and the CMC package expected in Q4 2026, targeting a 2027 launch. The therapy has FDA RMAT, Orphan Drug and Fast Track designations, and CEO Matthew B. Klein said the acquisition advances the company's strategy of leveraging its rare disease commercial infrastructure to accelerate near-term revenue growth. The acquisition is expected to close in Q3 2026, strengthening PTC's pipeline in rare genetic disorders.
PTCT ▲SGMO ▲
Biotech & Genomic Medicine ▲
RTTNews·14dRead more ▾
Biotech & Genomic Medicine▼

Sangamo Therapeutics enters asset sale agreements with Lilly and Astellas, files for Chapter 11

Sangamo Therapeutics has entered into two separate asset sale agreements with Eli Lilly and Astellas Pharma and simultaneously filed for voluntary Chapter 11 reorganization. Lilly will serve as stalking horse bidder for Sangamo's capsid delivery platform, zinc finger platform, modular integrase platform, and the prion disease program ST-506, while Astellas will serve as stalking horse bidder for the Fabry disease program isaralgagene civaparvovec, or ST-920. The court-supervised auction process is expected to include substantially all of Sangamo's assets, with certain other assets such as the ST-503 chronic neuropathic pain program and hemophilia A program giroctocogene fitelparvovec remaining available to interested bidders. Sangamo has secured a debtor-in-possession financing commitment from Northridge ATM, LLC to support ongoing operations during the proceedings. The company aims to maximize value for all stakeholders through the Chapter 11 process.
SGMO ▼4503.JP ▲LLY ▲
Biotech & Genomic Medicine ▼
GlobeNewswire·64dRead more ▾
Biotech & Genomic Medicine▼

Sangamo Therapeutics files for Chapter 11 bankruptcy protection

Sangamo Therapeutics has filed for Chapter 11 bankruptcy protection in Delaware, reporting both assets and liabilities estimated between $100 million and $500 million as it seeks to navigate worsening financial constraints. The biotech firm had recently retained Raymond James as its financial advisor to assist in evaluating a full range of strategic alternatives to advance its pipeline and maximize stakeholder value.
SGMO ▼
Biotech & Genomic Medicine ▼
Seeking Alpha·64dRead more ▾
© 2026 MarketDXAsset